The Cancer Pharmacology Core provides the necessary expertise and resources to design and undertake pharmacokinetic (PK) studies in Phase I and II clinical trials, and preclinical investigations. Services include the implementation and validation of previously developed analytical methods to quantify drugs and their metabolites in biological fluids, and modification or development of new assays. The Core also offers comprehensive analysis of pharmacokinetic data, including the estimation of pharmakinetic (PK) parameters and identifying their relationship to pathophysiological variables and pharmacodynamic effects. J. Supko (MGH) has led this facility since 2004. Director: Jeffrey G. Supko, PhD(MGH) Category: 1.37 (Pharmacokinetics &Drug Metabolism), 4.05 (Pharmacology) Management: Joint (Cancer Center and Institutional).
Pharmacokinetic (PK) studies are widely recognized as being essential to the development and evaluation of new drugs and combination regimens for the treatment of cancer. The Cancer Pharmacology Core provides DF/HCC investigators with all of the necessary capabilities to design and undertake PK studies in the context of preclinical investigations and early phase clinical trials. The ultimate goal of the Core is to facilitate the acquisition of informative PK data, that has a direct relevance to the clinical or preclinical evaluation of investigational chemotherapeutic agents, and make the data available to investigators in a timely manner.
|Lin, Ruei-Zeng; Lee, Chin Nien; Moreno-Luna, Rafael et al. (2017) Host non-inflammatory neutrophils mediate the engraftment of bioengineered vascular networks. Nat Biomed Eng 1:|
|Wang, Meng; Han, Jing; Marcar, Lynnette et al. (2017) Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway. Cancer Res 77:2018-2028|
|Ignatius, Myron S; Hayes, Madeline N; Lobbardi, Riadh et al. (2017) The NOTCH1/SNAIL1/MEF2C Pathway Regulates Growth and Self-Renewal in Embryonal Rhabdomyosarcoma. Cell Rep 19:2304-2318|
|Nugent, Alicia A; Park, Jong G; Wei, Yan et al. (2017) Mutant ?2-chimaerin signals via bidirectional ephrin pathways in Duane retraction syndrome. J Clin Invest 127:1664-1682|
|Breitkopf, Susanne B; Taveira, Mateus De Oliveira; Yuan, Min et al. (2017) Serial-omics of P53-/-, Brca1-/- Mouse Breast Tumor and Normal Mammary Gland. Sci Rep 7:14503|
|Bowden, John A; Heckert, Alan; Ulmer, Candice Z et al. (2017) Harmonizing lipidomics: NIST interlaboratory comparison exercise for lipidomics using SRM 1950-Metabolites in Frozen Human Plasma. J Lipid Res 58:2275-2288|
|Lindsley, R Coleman; Saber, Wael; Mar, Brenton G et al. (2017) Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. N Engl J Med 376:536-547|
|Mita, Monica M; Mita, Alain C; Moseley, Jennifer L et al. (2017) Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies. Br J Cancer 117:1258-1268|
|Hu, Yuebi; Alden, Ryan S; Odegaard, Justin I et al. (2017) Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients. Clin Cancer Res 23:7351-7359|
|Lam, Hilaire C; Liu, Heng-Jia; Baglini, Christian V et al. (2017) Rapamycin-induced miR-21 promotes mitochondrial homeostasis and adaptation in mTORC1 activated cells. Oncotarget 8:64714-64727|
Showing the most recent 10 out of 371 publications